Ben Dijk (DFZ Participaties):

Ben Dijk is Investment Director at De Friesland Participatiefonds, a captital venture fund of health insurance company De Friesland specially dedicated to healthcare innovations. Prior to DFZ Participaties he was an Investment Manager at Friesland Bank Investments, a private equity fund with a focus on medium sized companies. He has also advised the management board on the strategic portfolio of Friesland Bank. Before that he was responsible for building positions in listed small & medium sized companies. Ben holds a Master in Business Administration from the University of Groningen.

Oscar Slotboom, Member of the Supervisory Board:

Oskar joined SurgVision as a boardmember in January 2017. He joined BioGeneration as a partner in 2016 strengthening the team with his commercial, business development and consulting experience. Oskar started his career in McKinsey & Company as a management consultant. After that he held positions in Crucell, first as business development director and later he became responsible for the Pediatric Franchise. After the acquisition of Crucell by Johnson & Johnson, Oskar led the Vaccines & Infectious Diseases business unit in Johnson & Johnson's pharma joint venture Xian Janssen in Beijing, China. Prior to joining BioGeneration he was Chief Commercial Officer of Avantium, a leading chemical technology company and a forerunner in renewable chemistry. Oskar has a degree in chemical engineering from the Twente University (NL) and holds a MBA from INSEAD.

Rob de Ree, Chairman of the Supervisory Board:

Rob serves as the Chairman of the Supervisory board of SurgVision since December 2016. Rob has over 25 years' experience in the pharmaceutical and medtech industry in sales, marketing, business development and general management. Rob started his career in pharma in 1991 at the cardiovascular division of Byk Gulden in different roles in sales and marketing. Rob joined Medtronic international in 1996 where he was responsible for building the European venture business for the Octopus and other minimally invasive cardiac surgery products. During his 9-year tenure at Medtronic Rob moved to the Cardiac Rhythm Management division and in 2004 he was appointed European marketing director located in the Medtronic European headquarters in Switzerland. Rob moved to Crucell (senior Business Development Director) after which he joined the startup company BMEYE (hemodynamic monitoring) in June 2007 as the VP Sales & Marketing and was appointed CEO in January 2008.Under his leadership, BMEYE was successfully sold to Edwards Lifesciences in 2012. After a transition phase Rob left Edwards and joined Dezima Pharma as the CEO. Dezima pharma was sold to Amgen in October 2015 for a total deal value of up to $ 1.5 billion. Rob holds a MSc in pharmacy from the University of Groningen.